MedWatch

Sydbank: Lundbeck’s profit margin under pressure

Sydbank sees a rapidly declining profit margin for Lundbeck in the second quarter of the year compared with Q2 2011, but the bank remains optimistic about the share.

Foto: Lundbeck/PR

The declining sale of the antidepressant Lexapro in the US will have a significant impact on the coming Q2 financial statement from Lundbeck, add to that unforeseen costs for the announced organization restructuring, and it becomes clear that profit margins will be far from the numbers in the same period last year.

That’s the general conclusion from stock-analyst Søren Løntoft Hansen from Sydbank in a memo outlining the banks expectations prior to the financial statement from Lundbeck due August 8 at 8 am.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier